Gg again!!_老虎社区_美港股上老虎

2021-11-05

Gg again!!

Bionano Genomics stock tanked more than 8% in premarket trading<blockquote>Bionano Genomics 股价在盘前交易中下跌超过 8%</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":846408798,"tweetId":"846408798","gmtCreate":1636101521752,"gmtModify":1636101936380,"author":{"id":3585642689958579,"idStr":"3585642689958579","authorId":3585642689958579,"authorIdStr":"3585642689958579","name":"HeroSmurf","avatar":"https://static.tigerbbs.com/6015b234d96461c6ef8db8d919ac3473","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":23,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>Gg again!!</body></html>","htmlText":"<html><head></head><body>Gg again!!</body></html>","text":"Gg again!!","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/846408798","repostId":1194946622,"repostType":4,"repost":{"id":"1194946622","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636101187,"share":"https://www.laohu8.com/m/news/1194946622?lang=zh_CN&edition=full","pubTime":"2021-11-05 16:33","market":"us","language":"en","title":"Bionano Genomics stock tanked more than 8% in premarket trading<blockquote>Bionano Genomics 股价在盘前交易中下跌超过 8%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1194946622","media":"Tiger Newspress","summary":"Bionano Genomics stock tanked more than 8% in premarket trading after Bionano Genomics Q3 net loss $","content":"Bionano Genomics stock tanked more than 8% in premarket trading&nbsp;after&nbsp;Bionano Genomics Q3 net loss $20.753M, sales $4.66M beat $4.23M estimate.<blockquote>Bionano Genomics 第三季度净亏损 2075.3 万美元，销售额 466 万美元，超出 423 万美元预期，Bionano Genomics 股价在盘前交易中下跌超过 8%。</blockquote> <img src=\"https://static.tigerbbs.com/459633281a2e1ef6cef18931e8ba2b92\" tg-width=\"848\" tg-height=\"619\" width=\"100%\" height=\"auto\"><blockquote></blockquote> Bionano Genomics, Inc.&nbsp;reported financial results and business achievements for the quarter ended&nbsp;September&nbsp;30, 2021&nbsp;and highlighted recent corporate updates.<blockquote>比奥纳诺基因组学公司。报告截至2021年9月30日的季度的财务业绩和业务成就，并强调了最近的公司更新。</blockquote> – Acquisition of BioDiscovery transforms Bionano from the structural variation company into a data solutions provider with the potential to offer the most comprehensive variant analysis platform in genomics<blockquote>– 收购 BioDiscovery 将 Bionano 从结构变异公司转变为数据解决方案提供商，有潜力提供基因组学领域最全面的变异分析平台</blockquote> –&nbsp;Total revenue of$4.7 million, a 112% year-over-year total revenue increase, driven by growth in the Saphyr® installed base<blockquote>– 总收入为 470 万美元，受 Saphyr 增长推动，总收入同比增长 112%®安装底座</blockquote> –&nbsp;Record number of Saphyr shipments and installations for any quarter to date<blockquote>– 迄今为止任何季度蓝宝石出货量和安装量均创历史新高</blockquote> –&nbsp;Launched protocols for ultra-high molecular weight DNA isolation from amniocentesis and chorionic villus sampling (CVS) for prenatal applications<blockquote>-推出从羊膜穿刺术和绒毛取样（CVS）中分离超高分子量DNA以供产前应用的方案</blockquote> –&nbsp;Remaining 2021 milestones on track<blockquote>– 2021 年剩余里程碑步入正轨</blockquote> –&nbsp;Strong balance sheet with$326.1 millionin cash and short term investments as ofSeptember&nbsp;30, 2021<blockquote>– 截至 2021 年 9 月 30 日，资产负债表强劲，现金和短期投资达 3.261 亿美元</blockquote> “We had the strongest quarter in Bionano’s history with a record number of Saphyr shipments and installations, including adoptions at several notable sites, including leading hospitals, cytogenetics labs and academic medical centers around the world. With the acquisition of BioDiscovery, a leading software company with best-in-class solutions for analysis, visualization, interpretation and reporting of genomics data. for microarray and next-generation sequencing (NGS), we are transitioningBionano Genomicsfrom being the structural variation company into a data solutions provider. We believe this will enable access to an expanded market opportunity by leveraging the NGS market through software. We are extremely pleased with the progress we are making and the fact that outstanding leaders are joining Bionano to join us in transforming the way the world sees the genome,” commentedErik Holmlin, PhD, Chief Executive Officer ofBionano Genomics.<blockquote>“我们迎来了 Bionano 历史上最强劲的一个季度，蓝宝石的出货量和安装量创下了历史新高，其中包括在世界各地的领先医院、细胞遗传学实验室和学术医疗中心等多个著名场所采用蓝宝石。随着我们收购 BioDiscovery，这是一家领先的软件公司，为基因组学数据的分析、可视化、解释和报告提供一流的解决方案。对于微阵列和下一代测序 (NGS)，我们正在将 Bionano Genomics 从结构变异公司转变为数据解决方案提供商。我们相信，这将使我们能够通过软件利用NGS市场获得更多的市场机会。Bionano Genomics首席执行官Derik Holmlin博士评论道：“我们对我们正在取得的进展以及杰出的领导者加入Bionano，与我们一起改变世界看待基因组的方式感到非常高兴。</blockquote> Chris Stewart, Chief Financial Officer of Bionano added: “Q3 was another excellent quarter. We continued to achieve meaningful year-over-year revenue growth and maintained a strong balance sheet with$326 millionof cash and marketable securities as of the quarter-end. We also remain on track to achieve the milestones we laid out in the first quarter of 2021.”<blockquote>Bionano 首席财务官克里斯-斯图尔特（Chris Stewart）补充道： “第三季度又是一个出色的季度。我们继续实现有意义的同比收入增长，并保持了强劲的资产负债表，截至季度末，现金和有价证券为 3.26 亿美元。我们还有望实现 2021 年第一季度制定的里程碑。”</blockquote> Key Business Highlights in Q3<blockquote>第三季度主要业务亮点</blockquote> The Company executed on its commercialization strategy, built scientific momentum by presenting data at key scientific meetings and drove utilization of Saphyr at key institutions across the globe, with the following highlights:<blockquote>该公司执行其商业化战略，通过在重要科学会议上展示数据来建立科学势头，并推动全球主要机构使用 Saphyr，其亮点如下：</blockquote> –&nbsp;Expanded the installed base of Saphyr systems from 121 at the end of Q2 to 141 at the end of Q3. During the quarter endedSeptember 30,2021, we shipped a total of 24 Saphyr systems to the field, compared to 11 systems shipped in the same quarter in 2020.<blockquote>–将Saphyr systems的安装基数从第二季度末的121个扩大到第三季度末的141个截至 2021 年 9 月 30 日的季度，我们共向现场运送了 24 套 Saphyr 系统，而 2020 年同一季度运送了 11 套系统。</blockquote> –&nbsp;Sold 3,969 nanochannel array flow cells during the quarter endedSeptember 30, 2021,which is the most flow cells sold in any quarter ever and represents 122% growth over the same quarter in 2020.<blockquote>–截至 2021 年 9 月 30 日的季度内售出 3,969 个纳米通道阵列流动池，这是有史以来任何季度销量最高的流动池，比 2020 年同一季度增长了 122%。</blockquote> –&nbsp;Commercial release of solutions for isolation of ultra-high molecular weight DNA for prenatal applicationssupporting the use of samples derived from amniocentesis and CVS. Bionano Prep SP Amnio and CVS Culture DNA Isolation Protocol supports both fresh cultures and cryopreserved cells, which expands the markets served for OGM.<blockquote>–用于产前应用的超高分子量DNA分离溶液的商业释放支持使用来自羊膜穿刺术和CVS的样本。Bionano Prep SP羊膜和CVS培养物DNA分离方案支持新鲜培养物和冷冻保存的细胞，这扩大了转基因生物的市场。</blockquote> –&nbsp;OGM with Saphyr was adopted at several notable cytogenetics laboratories and academic medical centersinthe United States, including Brigham &amp; Woman’s Hospital, which is using OGM to identify structural variations in constitutional and cancer applications. Outside the US, Saphyr was adopted inAustralia,EuropeandChina.<blockquote>– 带有蓝宝石的OGM被几个著名的细胞遗传学实验室和学术医学中心采用在美国，包括布莱根妇女医院（Brigham &amp; Woman's Hospital），该医院正在利用转基因生物来识别体质和癌症应用中的结构变异。在美国以外，Saphyr 在澳大利亚、欧洲和中国被采用。</blockquote> –&nbsp;The largest clinical research study to date evaluating OGM was published inThe Journal of Molecular Diagnosticsfor a rare muscle disease, facioscapulohumeral muscular dystrophy, or FSHD, in about 351 patients. The results demonstrated that OGM provided data more quickly, accurately, and reproducibly than the current gold standard method of Southern blot analysis. The findings support the rationale for adopting OGM as an alternative to Southern blot analysis as OGM had a greater sizing accuracy as well as a greater than 99% concordance with Southern blot analysis.<blockquote>–迄今为止评估转基因生物的最大临床研究发表于分子诊断学杂志对于一种罕见的肌肉疾病，面肩肱肌营养不良症，或FSHD，在大约351名患者中。结果表明，与当前的Southern印迹分析金标准方法相比，OGM提供数据更快、更准确、更可重复。这些发现支持采用OGM作为Southern印迹分析替代方案的基本原理，因为OGM具有更高的尺寸准确性，并且与Southern印迹分析的一致性大于99%。</blockquote> –&nbsp;NuProbe Global, a global molecular diagnostics leader, adopted Saphyr to be integrated their proprietary tools,Quantitative Amplicon Sequencing (QASeq) and Blocker Displacement Amplification (BDA), for research and development efforts in reproductive health and oncology liquid biopsies.<blockquote>–全球分子诊断领导者NuProbe Global采用Saphyr集成其专有工具，定量扩增子测序（QASeq）和阻断剂置换扩增（BDA），用于生殖健康和肿瘤学液体活检的研发工作。</blockquote> –&nbsp;Saphyr customers and Bionano conducted 10 presentations at the Annual Cancer Genomics Consortium Meeting inmid-August 2021,highlighting the benefits of OGM for clinical research applications in solid tumor analysis, hematological malignancies, products of conception, prenatal and postnatal constitutional genetics. More than 500 participants from around the globe attended virtually, highlighting the strong interest in OGM for cancer genomics.<blockquote>–Saphyr 客户和 Bionano 在 2021 年 8 月中旬至 2021 年年度癌症基因组学联盟会议上进行了 10 场演讲，强调转基因生物在实体瘤分析、血液恶性肿瘤、受孕产品、产前和产后体质遗传学方面的临床研究应用的益处。来自全球各地的500多名参与者虚拟参加了会议，凸显了人们对转基因生物在癌症基因组学方面的浓厚兴趣。</blockquote> –&nbsp;Bionano customers presented 11 presentations on OGM at theEuropean Society of Human Genetics(ESHG) meeting in lateAugust 2021, demonstrating the clinical utility of OGM across many therapeutic application areas, along with the unique capabilities of Bionano’s Saphyr®system to detect all classes of structural variants, across the genome, at a superior resolution relative to traditional techniques.<blockquote>– Bionano 客户于 2021 年 8 月下旬在欧洲人类遗传学会 (ESHG) 会议上发表了 11 场关于转基因生物的演讲展示了转基因生物在许多治疗应用领域的临床实用性，以及 Bionano 蓝宝石的独特功能®相对于传统技术，以更高的分辨率检测整个基因组中所有类别的结构变异的系统。</blockquote> –&nbsp;Added exceptional talent across commercial leadership functions,includingAmanda Lettmannas Vice President of Global Customer Experience,Alex Helmas Vice President Strategic Product Marketing,Stephanie Hoyleas Vice President Corporate Marketing,Amanda Hernandezas Vice President of Global Sales Training and Development,Justin Leightonas Vice President and General Manager,Lineagen, andBob Hertsenbergas North America Sales Director.<blockquote>– 增加了商业领导职能的优秀人才，包括全球客户体验副总裁 Amanda Lettmannas、战略产品营销副总裁 Alex Helmas、企业营销副总裁 Stephanie Hoyleas、全球销售培训和发展副总裁 Amanda Hernandezas、Lineagen 副总裁兼总经理 Justin Leightonas 和北美销售总监 Bob Hertsenbergas。</blockquote> Financial Highlights<blockquote>财务摘要</blockquote> –&nbsp;Total revenue for the third quarter of 2021 was$4.7 million,up 21% from$3.9 millionin the second quarter and up 112% from$2.2 millionin the same period of 2020. The sequential increase was driven by increased demand for our Saphyr optical genome mapping solutions, including increased instrument sales and greater demand for our reagent rental program and consumables. The year-over-year increase was driven by both higher product sales and by the addition of revenue fromLineagen.<blockquote>–2021 年第三季度总收入为 470 万美元，比第二季度的390万美元增长21%，比2020年同期的220万美元增长112%。环比增长是由于对我们的蓝宝石光学基因组图谱解决方案的需求增加，包括仪器销售的增加以及对我们的试剂租赁计划和耗材的更大需求。同比增长是由产品销售增加和 Lineagen 收入增加推动的。</blockquote> –&nbsp;Gross margin for the third quarter of 2021 was 24.8%,compared to 37.3% in the prior quarter and 33.4% from the third quarter of 2020. The decrease was primarily due to an increase in laboratory and warranty related expense that are expected to be non-recurring.<blockquote>–2021年第三季度毛利率为24.8%，相比之下，上一季度为 37.3%，2020 年第三季度为 33.4%。该减少主要是由于实验室和保修相关开支增加，预计该开支不会经常性。</blockquote> –&nbsp;Third quarter operating expense was$21.8 million,compared to$17.9&nbsp;million in the prior quarter and$11.0 millionin the third quarter of 2020. The sequential increase was mainly due to a$1.8 millionincrease in headcount and related expenses and a$1.5 millionincrease in Research and Development expenses related to expanding our supply chain to produce higher volumes. Third quarter operating expense included$2.8 millionof non-cash stock-based compensation. The year-over-year increase was primarily due to increased headcount-related spending as we build out all facets of our organization to support our expected commercial progress and increased research and development costs.<blockquote>–第三季度运营费用为 2180 万美元，相比之下，上一季度为 1790 万美元，2020 年第三季度为 1100 万美元。环比增长主要是由于员工人数和相关费用增加180万澳元，以及与扩大供应链以生产更高产量相关的研发费用增加150万澳元。第三季度运营费用包括 280 万美元的非现金股票薪酬。同比增长主要是由于我们建立组织的各个方面以支持预期的商业进展以及增加的研发成本，员工人数相关支出增加。</blockquote> –&nbsp;AtSeptember&nbsp;30, 2021, the Company had cash, cash equivalents, and short-term investments of$326.1 millioncompared to cash and cash equivalents of$38.4 millionatDecember 31, 2020. The increase in cash is primarily due to the equity raises that were completed in the first quarter of 2021.<blockquote>– 截至2021年9月30日，公司拥有现金、现金等价物和短期投资3.261亿美元相比之下，截至 2020 年 12 月 31 日，现金和现金等价物为 3840 万美元。现金增加主要是由于2021年第一季度完成的股权融资。</blockquote> Remaining Anticipated Milestones for 2021 – Initiatives to Drive Global Adoption of Saphyr<blockquote>2021 年剩余预期里程碑 – 推动 Saphyr 全球采用的举措</blockquote> –&nbsp;4Q21: Interim publication of results from pediatric clinical study<blockquote>– 2021年第四季度：儿科临床研究结果中期公布</blockquote> –&nbsp;4Q21: Validation of LDTs by 3 sites in both our prenatal clinical study and our pediatric clinical study<blockquote>– 2021年第四季度：在我们的产前临床研究和儿科临床研究中，3个研究中心验证了LDT</blockquote> –&nbsp;4Q21: Initial prototype of next gen high throughput Saphyr<blockquote>– 2021年第四季度：下一代高通量蓝宝石的初始原型</blockquote> –&nbsp;4Q21: Reach installed base of 150 systems to achieve a 50% increase over year end 2020<blockquote>– 2021年第四季度：达到150套系统的安装基数，较2020年底增加50%</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bionano Genomics stock tanked more than 8% in premarket trading<blockquote>Bionano Genomics 股价在盘前交易中下跌超过 8%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBionano Genomics stock tanked more than 8% in premarket trading<blockquote>Bionano Genomics 股价在盘前交易中下跌超过 8%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nTiger Newspress \n2021-11-05 16:33\n</div>\n</a>\n</h4>\n</header>\n<article>\nBionano Genomics stock tanked more than 8% in premarket trading&nbsp;after&nbsp;Bionano Genomics Q3 net loss $20.753M, sales $4.66M beat $4.23M estimate.<blockquote>Bionano Genomics 第三季度净亏损 2075.3 万美元，销售额 466 万美元，超出 423 万美元预期，Bionano Genomics 股价在盘前交易中下跌超过 8%。</blockquote> <img src=\"https://static.tigerbbs.com/459633281a2e1ef6cef18931e8ba2b92\" tg-width=\"848\" tg-height=\"619\" width=\"100%\" height=\"auto\"><blockquote></blockquote> Bionano Genomics, Inc.&nbsp;reported financial results and business achievements for the quarter ended&nbsp;September&nbsp;30, 2021&nbsp;and highlighted recent corporate updates.<blockquote>比奥纳诺基因组学公司。报告截至2021年9月30日的季度的财务业绩和业务成就，并强调了最近的公司更新。</blockquote> – Acquisition of BioDiscovery transforms Bionano from the structural variation company into a data solutions provider with the potential to offer the most comprehensive variant analysis platform in genomics<blockquote>– 收购 BioDiscovery 将 Bionano 从结构变异公司转变为数据解决方案提供商，有潜力提供基因组学领域最全面的变异分析平台</blockquote> –&nbsp;Total revenue of$4.7 million, a 112% year-over-year total revenue increase, driven by growth in the Saphyr® installed base<blockquote>– 总收入为 470 万美元，受 Saphyr 增长推动，总收入同比增长 112%®安装底座</blockquote> –&nbsp;Record number of Saphyr shipments and installations for any quarter to date<blockquote>– 迄今为止任何季度蓝宝石出货量和安装量均创历史新高</blockquote> –&nbsp;Launched protocols for ultra-high molecular weight DNA isolation from amniocentesis and chorionic villus sampling (CVS) for prenatal applications<blockquote>-推出从羊膜穿刺术和绒毛取样（CVS）中分离超高分子量DNA以供产前应用的方案</blockquote> –&nbsp;Remaining 2021 milestones on track<blockquote>– 2021 年剩余里程碑步入正轨</blockquote> –&nbsp;Strong balance sheet with$326.1 millionin cash and short term investments as ofSeptember&nbsp;30, 2021<blockquote>– 截至 2021 年 9 月 30 日，资产负债表强劲，现金和短期投资达 3.261 亿美元</blockquote> “We had the strongest quarter in Bionano’s history with a record number of Saphyr shipments and installations, including adoptions at several notable sites, including leading hospitals, cytogenetics labs and academic medical centers around the world. With the acquisition of BioDiscovery, a leading software company with best-in-class solutions for analysis, visualization, interpretation and reporting of genomics data. for microarray and next-generation sequencing (NGS), we are transitioningBionano Genomicsfrom being the structural variation company into a data solutions provider. We believe this will enable access to an expanded market opportunity by leveraging the NGS market through software. We are extremely pleased with the progress we are making and the fact that outstanding leaders are joining Bionano to join us in transforming the way the world sees the genome,” commentedErik Holmlin, PhD, Chief Executive Officer ofBionano Genomics.<blockquote>“我们迎来了 Bionano 历史上最强劲的一个季度，蓝宝石的出货量和安装量创下了历史新高，其中包括在世界各地的领先医院、细胞遗传学实验室和学术医疗中心等多个著名场所采用蓝宝石。随着我们收购 BioDiscovery，这是一家领先的软件公司，为基因组学数据的分析、可视化、解释和报告提供一流的解决方案。对于微阵列和下一代测序 (NGS)，我们正在将 Bionano Genomics 从结构变异公司转变为数据解决方案提供商。我们相信，这将使我们能够通过软件利用NGS市场获得更多的市场机会。Bionano Genomics首席执行官Derik Holmlin博士评论道：“我们对我们正在取得的进展以及杰出的领导者加入Bionano，与我们一起改变世界看待基因组的方式感到非常高兴。</blockquote> Chris Stewart, Chief Financial Officer of Bionano added: “Q3 was another excellent quarter. We continued to achieve meaningful year-over-year revenue growth and maintained a strong balance sheet with$326 millionof cash and marketable securities as of the quarter-end. We also remain on track to achieve the milestones we laid out in the first quarter of 2021.”<blockquote>Bionano 首席财务官克里斯-斯图尔特（Chris Stewart）补充道： “第三季度又是一个出色的季度。我们继续实现有意义的同比收入增长，并保持了强劲的资产负债表，截至季度末，现金和有价证券为 3.26 亿美元。我们还有望实现 2021 年第一季度制定的里程碑。”</blockquote> Key Business Highlights in Q3<blockquote>第三季度主要业务亮点</blockquote> The Company executed on its commercialization strategy, built scientific momentum by presenting data at key scientific meetings and drove utilization of Saphyr at key institutions across the globe, with the following highlights:<blockquote>该公司执行其商业化战略，通过在重要科学会议上展示数据来建立科学势头，并推动全球主要机构使用 Saphyr，其亮点如下：</blockquote> –&nbsp;Expanded the installed base of Saphyr systems from 121 at the end of Q2 to 141 at the end of Q3. During the quarter endedSeptember 30,2021, we shipped a total of 24 Saphyr systems to the field, compared to 11 systems shipped in the same quarter in 2020.<blockquote>–将Saphyr systems的安装基数从第二季度末的121个扩大到第三季度末的141个截至 2021 年 9 月 30 日的季度，我们共向现场运送了 24 套 Saphyr 系统，而 2020 年同一季度运送了 11 套系统。</blockquote> –&nbsp;Sold 3,969 nanochannel array flow cells during the quarter endedSeptember 30, 2021,which is the most flow cells sold in any quarter ever and represents 122% growth over the same quarter in 2020.<blockquote>–截至 2021 年 9 月 30 日的季度内售出 3,969 个纳米通道阵列流动池，这是有史以来任何季度销量最高的流动池，比 2020 年同一季度增长了 122%。</blockquote> –&nbsp;Commercial release of solutions for isolation of ultra-high molecular weight DNA for prenatal applicationssupporting the use of samples derived from amniocentesis and CVS. Bionano Prep SP Amnio and CVS Culture DNA Isolation Protocol supports both fresh cultures and cryopreserved cells, which expands the markets served for OGM.<blockquote>–用于产前应用的超高分子量DNA分离溶液的商业释放支持使用来自羊膜穿刺术和CVS的样本。Bionano Prep SP羊膜和CVS培养物DNA分离方案支持新鲜培养物和冷冻保存的细胞，这扩大了转基因生物的市场。</blockquote> –&nbsp;OGM with Saphyr was adopted at several notable cytogenetics laboratories and academic medical centersinthe United States, including Brigham &amp; Woman’s Hospital, which is using OGM to identify structural variations in constitutional and cancer applications. Outside the US, Saphyr was adopted inAustralia,EuropeandChina.<blockquote>– 带有蓝宝石的OGM被几个著名的细胞遗传学实验室和学术医学中心采用在美国，包括布莱根妇女医院（Brigham &amp; Woman's Hospital），该医院正在利用转基因生物来识别体质和癌症应用中的结构变异。在美国以外，Saphyr 在澳大利亚、欧洲和中国被采用。</blockquote> –&nbsp;The largest clinical research study to date evaluating OGM was published inThe Journal of Molecular Diagnosticsfor a rare muscle disease, facioscapulohumeral muscular dystrophy, or FSHD, in about 351 patients. The results demonstrated that OGM provided data more quickly, accurately, and reproducibly than the current gold standard method of Southern blot analysis. The findings support the rationale for adopting OGM as an alternative to Southern blot analysis as OGM had a greater sizing accuracy as well as a greater than 99% concordance with Southern blot analysis.<blockquote>–迄今为止评估转基因生物的最大临床研究发表于分子诊断学杂志对于一种罕见的肌肉疾病，面肩肱肌营养不良症，或FSHD，在大约351名患者中。结果表明，与当前的Southern印迹分析金标准方法相比，OGM提供数据更快、更准确、更可重复。这些发现支持采用OGM作为Southern印迹分析替代方案的基本原理，因为OGM具有更高的尺寸准确性，并且与Southern印迹分析的一致性大于99%。</blockquote> –&nbsp;NuProbe Global, a global molecular diagnostics leader, adopted Saphyr to be integrated their proprietary tools,Quantitative Amplicon Sequencing (QASeq) and Blocker Displacement Amplification (BDA), for research and development efforts in reproductive health and oncology liquid biopsies.<blockquote>–全球分子诊断领导者NuProbe Global采用Saphyr集成其专有工具，定量扩增子测序（QASeq）和阻断剂置换扩增（BDA），用于生殖健康和肿瘤学液体活检的研发工作。</blockquote> –&nbsp;Saphyr customers and Bionano conducted 10 presentations at the Annual Cancer Genomics Consortium Meeting inmid-August 2021,highlighting the benefits of OGM for clinical research applications in solid tumor analysis, hematological malignancies, products of conception, prenatal and postnatal constitutional genetics. More than 500 participants from around the globe attended virtually, highlighting the strong interest in OGM for cancer genomics.<blockquote>–Saphyr 客户和 Bionano 在 2021 年 8 月中旬至 2021 年年度癌症基因组学联盟会议上进行了 10 场演讲，强调转基因生物在实体瘤分析、血液恶性肿瘤、受孕产品、产前和产后体质遗传学方面的临床研究应用的益处。来自全球各地的500多名参与者虚拟参加了会议，凸显了人们对转基因生物在癌症基因组学方面的浓厚兴趣。</blockquote> –&nbsp;Bionano customers presented 11 presentations on OGM at theEuropean Society of Human Genetics(ESHG) meeting in lateAugust 2021, demonstrating the clinical utility of OGM across many therapeutic application areas, along with the unique capabilities of Bionano’s Saphyr®system to detect all classes of structural variants, across the genome, at a superior resolution relative to traditional techniques.<blockquote>– Bionano 客户于 2021 年 8 月下旬在欧洲人类遗传学会 (ESHG) 会议上发表了 11 场关于转基因生物的演讲展示了转基因生物在许多治疗应用领域的临床实用性，以及 Bionano 蓝宝石的独特功能®相对于传统技术，以更高的分辨率检测整个基因组中所有类别的结构变异的系统。</blockquote> –&nbsp;Added exceptional talent across commercial leadership functions,includingAmanda Lettmannas Vice President of Global Customer Experience,Alex Helmas Vice President Strategic Product Marketing,Stephanie Hoyleas Vice President Corporate Marketing,Amanda Hernandezas Vice President of Global Sales Training and Development,Justin Leightonas Vice President and General Manager,Lineagen, andBob Hertsenbergas North America Sales Director.<blockquote>– 增加了商业领导职能的优秀人才，包括全球客户体验副总裁 Amanda Lettmannas、战略产品营销副总裁 Alex Helmas、企业营销副总裁 Stephanie Hoyleas、全球销售培训和发展副总裁 Amanda Hernandezas、Lineagen 副总裁兼总经理 Justin Leightonas 和北美销售总监 Bob Hertsenbergas。</blockquote> Financial Highlights<blockquote>财务摘要</blockquote> –&nbsp;Total revenue for the third quarter of 2021 was$4.7 million,up 21% from$3.9 millionin the second quarter and up 112% from$2.2 millionin the same period of 2020. The sequential increase was driven by increased demand for our Saphyr optical genome mapping solutions, including increased instrument sales and greater demand for our reagent rental program and consumables. The year-over-year increase was driven by both higher product sales and by the addition of revenue fromLineagen.<blockquote>–2021 年第三季度总收入为 470 万美元，比第二季度的390万美元增长21%，比2020年同期的220万美元增长112%。环比增长是由于对我们的蓝宝石光学基因组图谱解决方案的需求增加，包括仪器销售的增加以及对我们的试剂租赁计划和耗材的更大需求。同比增长是由产品销售增加和 Lineagen 收入增加推动的。</blockquote> –&nbsp;Gross margin for the third quarter of 2021 was 24.8%,compared to 37.3% in the prior quarter and 33.4% from the third quarter of 2020. The decrease was primarily due to an increase in laboratory and warranty related expense that are expected to be non-recurring.<blockquote>–2021年第三季度毛利率为24.8%，相比之下，上一季度为 37.3%，2020 年第三季度为 33.4%。该减少主要是由于实验室和保修相关开支增加，预计该开支不会经常性。</blockquote> –&nbsp;Third quarter operating expense was$21.8 million,compared to$17.9&nbsp;million in the prior quarter and$11.0 millionin the third quarter of 2020. The sequential increase was mainly due to a$1.8 millionincrease in headcount and related expenses and a$1.5 millionincrease in Research and Development expenses related to expanding our supply chain to produce higher volumes. Third quarter operating expense included$2.8 millionof non-cash stock-based compensation. The year-over-year increase was primarily due to increased headcount-related spending as we build out all facets of our organization to support our expected commercial progress and increased research and development costs.<blockquote>–第三季度运营费用为 2180 万美元，相比之下，上一季度为 1790 万美元，2020 年第三季度为 1100 万美元。环比增长主要是由于员工人数和相关费用增加180万澳元，以及与扩大供应链以生产更高产量相关的研发费用增加150万澳元。第三季度运营费用包括 280 万美元的非现金股票薪酬。同比增长主要是由于我们建立组织的各个方面以支持预期的商业进展以及增加的研发成本，员工人数相关支出增加。</blockquote> –&nbsp;AtSeptember&nbsp;30, 2021, the Company had cash, cash equivalents, and short-term investments of$326.1 millioncompared to cash and cash equivalents of$38.4 millionatDecember 31, 2020. The increase in cash is primarily due to the equity raises that were completed in the first quarter of 2021.<blockquote>– 截至2021年9月30日，公司拥有现金、现金等价物和短期投资3.261亿美元相比之下，截至 2020 年 12 月 31 日，现金和现金等价物为 3840 万美元。现金增加主要是由于2021年第一季度完成的股权融资。</blockquote> Remaining Anticipated Milestones for 2021 – Initiatives to Drive Global Adoption of Saphyr<blockquote>2021 年剩余预期里程碑 – 推动 Saphyr 全球采用的举措</blockquote> –&nbsp;4Q21: Interim publication of results from pediatric clinical study<blockquote>– 2021年第四季度：儿科临床研究结果中期公布</blockquote> –&nbsp;4Q21: Validation of LDTs by 3 sites in both our prenatal clinical study and our pediatric clinical study<blockquote>– 2021年第四季度：在我们的产前临床研究和儿科临床研究中，3个研究中心验证了LDT</blockquote> –&nbsp;4Q21: Initial prototype of next gen high throughput Saphyr<blockquote>– 2021年第四季度：下一代高通量蓝宝石的初始原型</blockquote> –&nbsp;4Q21: Reach installed base of 150 systems to achieve a 50% increase over year end 2020<blockquote>– 2021年第四季度：达到150套系统的安装基数，较2020年底增加50%</blockquote>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194946622","content_text":"Bionano Genomics stock tanked more than 8% in premarket trading after Bionano Genomics Q3 net loss $20.753M, sales $4.66M beat $4.23M estimate.\n\nBionano Genomics, Inc. reported financial results and business achievements for the quarter ended September 30, 2021 and highlighted recent corporate updates.\n– Acquisition of BioDiscovery transforms Bionano from the structural variation company into a data solutions provider with the potential to offer the most comprehensive variant analysis platform in genomics\n– Total revenue of$4.7 million, a 112% year-over-year total revenue increase, driven by growth in the Saphyr® installed base\n– Record number of Saphyr shipments and installations for any quarter to date\n– Launched protocols for ultra-high molecular weight DNA isolation from amniocentesis and chorionic villus sampling (CVS) for prenatal applications\n– Remaining 2021 milestones on track\n– Strong balance sheet with$326.1 millionin cash and short term investments as ofSeptember 30, 2021\n“We had the strongest quarter in Bionano’s history with a record number of Saphyr shipments and installations, including adoptions at several notable sites, including leading hospitals, cytogenetics labs and academic medical centers around the world. With the acquisition of BioDiscovery, a leading software company with best-in-class solutions for analysis, visualization, interpretation and reporting of genomics data. for microarray and next-generation sequencing (NGS), we are transitioningBionano Genomicsfrom being the structural variation company into a data solutions provider. We believe this will enable access to an expanded market opportunity by leveraging the NGS market through software. We are extremely pleased with the progress we are making and the fact that outstanding leaders are joining Bionano to join us in transforming the way the world sees the genome,” commentedErik Holmlin, PhD, Chief Executive Officer ofBionano Genomics.\nChris Stewart, Chief Financial Officer of Bionano added: “Q3 was another excellent quarter. We continued to achieve meaningful year-over-year revenue growth and maintained a strong balance sheet with$326 millionof cash and marketable securities as of the quarter-end. We also remain on track to achieve the milestones we laid out in the first quarter of 2021.”\nKey Business Highlights in Q3\nThe Company executed on its commercialization strategy, built scientific momentum by presenting data at key scientific meetings and drove utilization of Saphyr at key institutions across the globe, with the following highlights:\n– Expanded the installed base of Saphyr systems from 121 at the end of Q2 to 141 at the end of Q3. During the quarter endedSeptember 30,2021, we shipped a total of 24 Saphyr systems to the field, compared to 11 systems shipped in the same quarter in 2020.\n– Sold 3,969 nanochannel array flow cells during the quarter endedSeptember 30, 2021,which is the most flow cells sold in any quarter ever and represents 122% growth over the same quarter in 2020.\n– Commercial release of solutions for isolation of ultra-high molecular weight DNA for prenatal applicationssupporting the use of samples derived from amniocentesis and CVS. Bionano Prep SP Amnio and CVS Culture DNA Isolation Protocol supports both fresh cultures and cryopreserved cells, which expands the markets served for OGM.\n– OGM with Saphyr was adopted at several notable cytogenetics laboratories and academic medical centersinthe United States, including Brigham & Woman’s Hospital, which is using OGM to identify structural variations in constitutional and cancer applications. Outside the US, Saphyr was adopted inAustralia,EuropeandChina.\n– The largest clinical research study to date evaluating OGM was published inThe Journal of Molecular Diagnosticsfor a rare muscle disease, facioscapulohumeral muscular dystrophy, or FSHD, in about 351 patients. The results demonstrated that OGM provided data more quickly, accurately, and reproducibly than the current gold standard method of Southern blot analysis. The findings support the rationale for adopting OGM as an alternative to Southern blot analysis as OGM had a greater sizing accuracy as well as a greater than 99% concordance with Southern blot analysis.\n– NuProbe Global, a global molecular diagnostics leader, adopted Saphyr to be integrated their proprietary tools,Quantitative Amplicon Sequencing (QASeq) and Blocker Displacement Amplification (BDA), for research and development efforts in reproductive health and oncology liquid biopsies.\n– Saphyr customers and Bionano conducted 10 presentations at the Annual Cancer Genomics Consortium Meeting inmid-August 2021,highlighting the benefits of OGM for clinical research applications in solid tumor analysis, hematological malignancies, products of conception, prenatal and postnatal constitutional genetics. More than 500 participants from around the globe attended virtually, highlighting the strong interest in OGM for cancer genomics.\n– Bionano customers presented 11 presentations on OGM at theEuropean Society of Human Genetics(ESHG) meeting in lateAugust 2021, demonstrating the clinical utility of OGM across many therapeutic application areas, along with the unique capabilities of Bionano’s Saphyr®system to detect all classes of structural variants, across the genome, at a superior resolution relative to traditional techniques.\n– Added exceptional talent across commercial leadership functions,includingAmanda Lettmannas Vice President of Global Customer Experience,Alex Helmas Vice President Strategic Product Marketing,Stephanie Hoyleas Vice President Corporate Marketing,Amanda Hernandezas Vice President of Global Sales Training and Development,Justin Leightonas Vice President and General Manager,Lineagen, andBob Hertsenbergas North America Sales Director.\nFinancial Highlights\n– Total revenue for the third quarter of 2021 was$4.7 million,up 21% from$3.9 millionin the second quarter and up 112% from$2.2 millionin the same period of 2020. The sequential increase was driven by increased demand for our Saphyr optical genome mapping solutions, including increased instrument sales and greater demand for our reagent rental program and consumables. The year-over-year increase was driven by both higher product sales and by the addition of revenue fromLineagen.\n– Gross margin for the third quarter of 2021 was 24.8%,compared to 37.3% in the prior quarter and 33.4% from the third quarter of 2020. The decrease was primarily due to an increase in laboratory and warranty related expense that are expected to be non-recurring.\n– Third quarter operating expense was$21.8 million,compared to$17.9 million in the prior quarter and$11.0 millionin the third quarter of 2020. The sequential increase was mainly due to a$1.8 millionincrease in headcount and related expenses and a$1.5 millionincrease in Research and Development expenses related to expanding our supply chain to produce higher volumes. Third quarter operating expense included$2.8 millionof non-cash stock-based compensation. The year-over-year increase was primarily due to increased headcount-related spending as we build out all facets of our organization to support our expected commercial progress and increased research and development costs.\n– AtSeptember 30, 2021, the Company had cash, cash equivalents, and short-term investments of$326.1 millioncompared to cash and cash equivalents of$38.4 millionatDecember 31, 2020. The increase in cash is primarily due to the equity raises that were completed in the first quarter of 2021.\nRemaining Anticipated Milestones for 2021 – Initiatives to Drive Global Adoption of Saphyr\n– 4Q21: Interim publication of results from pediatric clinical study\n– 4Q21: Validation of LDTs by 3 sites in both our prenatal clinical study and our pediatric clinical study\n– 4Q21: Initial prototype of next gen high throughput Saphyr\n– 4Q21: Reach installed base of 150 systems to achieve a 50% increase over year end 2020","news_type":1,"symbols_score_info":{"BNGO":0.9}},"isVote":1,"tweetType":1,"viewCount":703,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":9,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/846408798"}